Alta Copper Corporation (QX) (ATCUF) News

Agenus to Provide Second Quarter 2024 Financial Report and Corporate Update

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company...

Agenus Announces End-of-Phase-2 Meeting Outcomes and Topline Interim Phase 2 Data for BOT/BAL in MSS Colorectal Cancer

Agreement reached with the FDA on Phase 3 dose for the BOT/BAL combination Accelerated approval pathway discouraged by FDA Preliminary Phase 2...

Significant Tumor Reductions in Neoadjuvant MSS Colon Cancer Patients Treated with Botensilimab/Balstilimab Presented at ESMO GI Conference

Extended BOT/BAL Therapy Yields Pronounced Improvements in Tumor Reductions Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel...

Cancer Therapy Evaluation Program Announces Availability of Botensilimab for Clinical Studies

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced that the...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Agenus Announces Appointment of Dr. Jennifer Buell to Its Board of Directors

Strategic leadership to drive next phase of growth for the company Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel...

Form 8-K - Current report

Nature Medicine Reports Agenus’ Novel Immunotherapy Demonstrates Clinical Activity Against a Deadly Form of Colorectal Cancer on the Rise in Americans Under 50

BOT/BAL Combination Shows Promising Results in the Most Prevalent Form of Colorectal Cancer, Affecting 95% of Diagnosed Patients Agenus has...

Agenus Announces Virtual Annual Shareholders Meeting

Agenus Inc. (“Agenus”) (NASDAQ: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today...

Form 8-K - Current report

Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today...